Stockscreener 앱 받기
37.93
3.93%
-1.55
시장 영업 전:
39.99
2.06
+5.43%
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach - Benzinga
Bristol Myers' Camzyos Update Boosts Prospects for Cytokinetics (CYTK) | BMY Stock News - GuruFocus
Stifel maintains Cytokinetics stock buy rating, $87 target By Investing.com - Investing.com India
US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble - insights.citeline.com
Is Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now? - Yahoo
10 Best High Short Interest Stocks to Buy Now - Insider Monkey
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics Strategic Talent Push: 13 New Hires Receive Major Equity Package Worth $3.9M - Stock Titan
Cytokinetics director John Henderson sells $123,325 in stock By Investing.com - Investing.com South Africa
Cytokinetics director John Henderson sells $123,325 in stock - Investing.com Australia
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It - MSN
Cytokinetics (CYTK) Gains Favor as Key Trial by Bristol-Myers Fa - GuruFocus
Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten - insights.citeline.com
JMP maintains $78 target on Cytokinetics stock after trial update By Investing.com - Investing.com Canada
Cytokinetics falls after rival Bristol Myers' heart drug fails trial - TradingView
BofA Adjusts Price Target for Cytokinetics (CYTK) Amid Competiti - GuruFocus
Bristol Myers stumbles in bid to widen heart drug’s use - Yahoo Finance
Citi Analysts Include Cytokinetics (CYTK) in 2025 North America Focus List | CYTK Stock News - GuruFocus
Cytokinetics, IncorporatedCommon Stock (NQ: CYTK - FinancialContent
Cytokinetics CEO Robert Blum sells $183,850 in stock By Investing.com - Investing.com South Africa
Cytokinetics CEO Robert Blum sells $183,850 in stock - Investing.com Australia
Cytokinetics rises as Edgewise posts mid-stage trial data for heart disorder therapy - MSN
JMP reiterates Cytokinetics stock with $78 target on HCM trial optimism - Investing.com Canada
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - GlobeNewswire
Exclusive: Cardiometabolic biotech gets $57.5M Series B, with help from Cytokinetics - Endpoints News
Optimistic Buy Rating on Cytokinetics Driven by Promising Aficamten Trial Outcomes - TipRanks
Cytokinetics stock plunges to 52-week low of $33.67 By Investing.com - Investing.com Canada
Cytokinetics’ CK-4021586 improves cardiac function in HFpEF - BioWorld MedTech
Cytokinetics (NASDAQ:CYTK) Given "Buy" Rating at HC Wainwright - MarketBeat
Cytokinetics EVP sells $72,360 in stock By Investing.com - Investing.com South Africa
Cytokinetics EVP sells $72,360 in stock - Investing.com Australia
Cytokinetics' SWOT analysis: aficamten potential drives stock outlook - Investing.com
Cytokinetics at Needham Conference: Strategic Moves in Cardiovascular Health By Investing.com - Investing.com Canada
Cytokinetics CCO Andrew Callos sells $103k in stock By Investing.com - Investing.com India
Cytokinetics CCO Andrew Callos sells $103k in stock - Investing.com
Cytokinetics at Needham Conference: Strategic Moves in Cardiovascular Health - Investing.com
Cytokinetics director Robert Harrington sells shares worth $17,743 By Investing.com - Investing.com South Africa
Cytokinetics director Robert Harrington sells shares worth $17,743 - Investing.com Australia
H.C. Wainwright maintains $120 target on Cytokinetics stock By Investing.com - Investing.com Canada
Cytokinetics stock holds $78 target from JMP amid trial results By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains overweight on Cytokinetics stock By Investing.com - Investing.com Canada
Cytokinetics stock holds $78 target from JMP amid trial results - Investing.com
CYTK Gains as EWTX Data and Fundraising Impact Stock Movement - GuruFocus
Why These Two Biotech Stocks Just Diverged - Investor's Business Daily
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' - Investopedia
Raymond James maintains Cytokinetics stock with $81 target By Investing.com - Investing.com UK
Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals
Cytokinetics stock rises on Edgewise data for lead drug (EWTX) - Seeking Alpha
Cytokinetics CEO compensation jumps 64%, thanks in large part to stock awardsSan Francisco Business Times - The Business Journals
Cytokinetics CEO Makes Major Stock Move! - TipRanks
Former Gilead legal star departs Cytokinetics as crucial FDA ruling approachesSan Francisco Business Times - The Business Journals
0.15%
4.32%
자본화:
|
볼륨(24시간):